Basilea Pharmaceutica (XSWX:BSLN) Total Stockholders Equity: CHF127.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
63 GF Score
Price CHF53.00
GF Value CHF58.23
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Total Stockholders Equity?

Basilea Pharmaceutica XSWX:BSLN +0.76% 63 Total Stockholders Equity is CHF127.9 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 63/100 and a GF Value™ of CHF58.23 (Fairly Valued). The stock has 2 warning signs investors should review.

Basilea Pharmaceutica's Total Stockholders Equity for the quarter that ended in Dec. 2025 was CHF127.9 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Basilea Pharmaceutica's Book Value per Share for the quarter that ended in Dec. 2025 was CHF10.41. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Basilea Pharmaceutica's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.70.

Basilea Pharmaceutica  (XSWX:BSLN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Basilea Pharmaceutica's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(127.941-0)/12.292
=10.41

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Basilea Pharmaceutica's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.062 + 87.155) / 127.941
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Total Stockholders Equity Related Terms

Basilea Pharmaceutica Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Total Stockholders Equity Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -58.61 -20.71 -10.00 81.00 127.94

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.00 16.79 81.00 103.16 127.94
XSWX:BSLN
63GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of CHF127.9 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Total Stockholders Equity of CHF127.9 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Total Stockholders Equity too high?
Basilea Pharmaceutica's current Total Stockholders Equity is CHF127.9 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Total Stockholders Equity compare to VRTX and REGN?
Basilea Pharmaceutica's Total Stockholders Equity of CHF127.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Total Stockholders Equity is CHF127.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF58.23, compared to a current price of CHF53.00 — trading 9% below its estimated fair value. The current Total Stockholders Equity is CHF127.9 Mil. Basilea Pharmaceutica's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Total Stockholders Equity is CHF127.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF53.00 is trading 9% below its estimated GF Value™ of CHF58.23. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Total Stockholders Equity: CHF127.9 Mil
  • GF Value™: CHF58.23 vs. price of CHF53.00 (9% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
63GF Score

Get the complete analysis for XSWX:BSLN

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF53.00
Price
CHF58.23
GF Value